About-cancer / kurapwa / kiriniki-miedzo / testicular-gomarara
Clinical Miedzo yekurapa Testicular Kenza
Miedzo 1-4 ye4
Nivolumab uye Ipilimumab Mukurapa Varwere vane Rare Tumors
Ichi chikamu II chidzidzo chekuyedza nivolumab uye ipilimumab mukurapa varwere vane tumarara tusingawanzo. Immunotherapy ine monoclonal antibodies, senge nivolumab uye ipilimumab, inogona kubatsira immune system kurwisa gomarara, uye inogona kukanganisa kugona kwesimba remarara kukura nekupararira. Uyu muedzo unonyora vatori vechikamu kune anotevera macohort anoenderana nemamiriro ezvinhu: 1. Epithelial tumors yemhino mhango, sinuses, nasopharynx: A) squamous cell carcinoma ine akasiyana emhino mhango, sinuses, uye nasopharynx uye trachea (kusanganisa laryngeal, nasopharyngeal cancer [NPC] , uye squamous cell carcinoma yemusoro nemutsipa [SCCHN]) B) Adenocarcinoma uye akasiyana emumhino, matadza, uye nasopharynx (yakavharwa kusvika pakuwedzera 07/27/2018) 2. Epithelial tumors yematota makuru emate (akavharwa kusvika mukuwedzera 03 / 20/2018) 3. Salivary gland mhando tumota dzemusoro nemutsipa, muromo, esophagus, dumbu, trachea nemapapu, zamu uye imwe nzvimbo (yakavharwa kusvika pakuwedzera) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. squamous cell carcinoma ine akasiyana eGI turakiti (mudumbu mudumbu ura, colon, rectum, pancreas) (yakavharwa kusvika mukuwedzera 10/17/2018) 7. Fibromixoma uye yakadzika giredhi mucinous adenocarcinoma (pseudomixoma peritonei) ye appendikisi uye ovary (yakavharwa kusvika pakuwedzera 03/20/2018) 8. Kazhinji maronda epancreatic anosanganisira acinar cell carcinoma, mucinous cystadenocarcinoma kana serous cystadenocarcinoma. Pancreatic adenocarcinoma haina kukodzera 9. Intrahepatic cholangiocarcinoma (yakavharwa kusvika mukuwedzera 03/20/2018) 10. Extrahepatic cholangiocarcinoma uye bile duct tumors (yakavharwa kusvika mukuwedzera 03/20/2018) 11. Sarcomatoid carcinoma yemapapu 12. Bronchoalveolar carcinoma lung. Mamiriro ezvinhu aya ave kunzi adenocarcinoma in situ, adenocarcinoma inowanda zvishoma, lepidic yakanyanya adenocarcinoma, kana inopinza mucinous adenocarcinoma 13. Zvisiri-epithelial tumors dzeovary: A) Germ cell cell tumarara temaovary B) Mullerian yakavhenganiswa bundu uye adenosarcoma (yakavharwa Kuwedzera 03/30/2018) 14. Bundu reTrophoblastic: A) Choriocarcinoma (yakavharwa kusvika pakuwedzera) 15. Transitional cell carcinoma kunze kweiyo renal, chiuno, ureter, kana dundira (yakavharwa kusvika pakuwedzera) 16. Bundu repamuviri testes uye extragonadal germ tumors: A) Seminoma uye testicular kenza tambo kenza B) Isina-seminomatous bundu C) Teratoma ine yakaipa shanduko (yakavharwa kusvika pakuwedzera) 17.
Nzvimbo: 895 nzvimbo
Kushanda Kwekutarisa, Bleomycin, Carboplatin, Etoposide, kana Cisplatin Mukurapa Kwevana uye Vakuru Varwere vaneGerm Cell Tumors Iyi chikamu chechitatu cheyedzo inoongorora mashandiro ekuongorora, bleomycin, carboplatin, etoposide, kana cisplatin inoshanda pakurapa kwevarwere uye vakuru varwere vane hutachiona hwemaseru. . Kushanda kwekutarisa kunogona kubatsira vanachiremba kuongorora zvidzidzo zvine njodzi yakadzika yemajemusi maseru mamota mushure mekunge bundu ravo rabviswa. Zvinodhaka zvinoshandiswa mukemotherapy, senge bleomycin, carboplatin, etoposide, uye cisplatin, zvinoshanda nenzira dzakasiyana kumisa kukura kwemarara maseru, kungave nekuuraya iwo maseru, nekuamisa iwo kubva pakupatsanuka, kana nekuamisa iwo kubva pakupararira. Nzvimbo: 460 nzvimbo
Inotuzumab Ozogamicin uye Post-Induction Chemotherapy Mukurapa Varwere vane High-Risk B-ZONSE, Mixed Phenotype Acute Leukemia, uye B-LLy
Ichi chikamu chechitatu cheyedzo yekuongorora kuti inotuzumab ozogamicin yakawedzera kune post-induction chemotherapy yevarwere vane High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) inovandudza mhedzisiro. Uyu muedzo unoongororawo mhedzisiro yevarwere vane yakavhenganiswa phenotype acute leukemia (MPAL), uye B-lymphoblastic lymphoma (B-LLy) painorapwa neZVESE kurapwa pasina inotuzumab ozogamicin. Inotuzumab ozogamicin inonzi monoclonal antibody, inonzi inotuzumab, yakabatana nemhando yekemotherapy inonzi calicheamicin. Inotuzumab inonamatira kune cancer maseru munzira yakanangwa uye inopa calicheamicin kuvauraya. Mimwe mishonga inoshandiswa mune chemotherapy regimen, senge cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, uye pegaspargase inoshanda nenzira dzakasiyana kumisa kukura kwemasero ekenza, kungave nekuuraya maseru, nekuamisa kuti asaparadzane, kana nekuamisa iwo kuti asapararire. Uyu muedzo unozoongororawo mhedzisiro yevarwere vane yakavhenganiswa phenotype acute leukemia (MPAL) uye vakaparadzira B lymphoblastic lymphoma (B-LLy) kana ichirapwa nenjodzi huru ZESE chemotherapy. Chinangwa chikuru chechidzidzo ichi ndechekunzwisisa kana kuwedzera inotuzumab ozogamicin kune yakajairwa yekuchengetedza chemotherapy inochengetedza kana kuvandudza mhedzisiro muHigh Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). Chikamu chekutanga chekudzidza chinosanganisira maviri ekutanga marapirwo erapi: Induction uye Kubatanidzwa. Chikamu ichi chinotora ruzivo nezve leukemia, pamwe nemhedzisiro yekurapa kwekutanga, kuitira kuti varwere vapinde mumapoka ekusimbisa ekurapa. Pachikamu chechipiri chechidzidzo ichi, varwere vanogashira iyo yasara yemakemotherapy macircuit (epamberi kugadzirisa ini, kunonoka kuwedzera, kugadzirisa kwepakati II, kugadzirisa), nevamwe varwere vakasarudzika kugamuchira inotuzumab. Zvimwe zvinangwa zvechidzidzo ichi zvinosanganisira kuongorora kuti kurapa vese varume nevakadzi nehurefu hwakafanana hwemakemotherapy inochengetedza mhedzisiro yevanhurume vakamborapwa kwegore rekuwedzera zvichienzaniswa nevasikana, pamwe nekuongorora nzira dzakanakisa dzekubatsira varwere kutevedzera pamuromo. chemotherapy marongero. Chekupedzisira, chidzidzo ichi chichava chekutanga kuongorora zvinobuda muzvidzidzo zvakaparadzirwa B-cell Lymphoblastic Leukemia (B LLy) kana Mixed Phenotype Acute Leukemia (MPAL) painorapwa neB-ALL chemotherapy. varwere vanogashira iyo yasara yemakemotherapy macircuit (epakati ekugadzirisa ini, kunonoka kuwedzera, kugadzirisa kwepakati II, kugadzirisa), nevamwe varwere vakasarudzika kugamuchira inotuzumab. Zvimwe zvinangwa zvechidzidzo ichi zvinosanganisira kuongorora kuti kurapa vese varume nevakadzi nehurefu hwakafanana hwemakemotherapy inochengetedza mhedzisiro yevanhurume vakamborapwa kwegore rekuwedzera zvichienzaniswa nevasikana, pamwe nekuongorora nzira dzakanakisa dzekubatsira varwere kutevedzera pamuromo. chemotherapy marongero. Chekupedzisira, chidzidzo ichi chichava chekutanga kuongorora zvinobuda muzvidzidzo zvakaparadzirwa B-cell Lymphoblastic Leukemia (B LLy) kana Mixed Phenotype Acute Leukemia (MPAL) painorapwa neB-ALL chemotherapy. varwere vanogashira iyo yasara yemakemotherapy macircuit (epakati ekugadzirisa ini, kunonoka kuwedzera, kugadzirisa kwepakati II, kugadzirisa), nevamwe varwere vakasarudzika kugamuchira inotuzumab. Zvimwe zvinangwa zvechidzidzo ichi zvinosanganisira kuongorora kuti kurapa vese varume nevakadzi nehurefu hwakafanana hwemakemotherapy inochengetedza mhedzisiro yevanhurume vakamborapwa kwegore rekuwedzera zvichienzaniswa nevasikana, pamwe nekuongorora nzira dzakanakisa dzekubatsira varwere kutevedzera pamuromo. chemotherapy marongero. Chekupedzisira, chidzidzo ichi chichava chekutanga kuongorora zvinobuda muzvidzidzo zvakaparadzirwa B-cell Lymphoblastic Leukemia (B LLy) kana Mixed Phenotype Acute Leukemia (MPAL) painorapwa neB-ALL chemotherapy. Zvimwe zvinangwa zvechidzidzo ichi zvinosanganisira kuongorora kuti kurapa vese varume nevakadzi nehurefu hwakafanana hwemakemotherapy inochengetedza mhedzisiro yevanhurume vakamborapwa kwegore rekuwedzera zvichienzaniswa nevasikana, pamwe nekuongorora nzira dzakanakisa dzekubatsira varwere kutevedzera pamuromo. chemotherapy marongero. Chekupedzisira, chidzidzo ichi chichava chekutanga kuongorora zvinobuda muzvidzidzo zvakaparadzirwa B-cell Lymphoblastic Leukemia (B LLy) kana Mixed Phenotype Acute Leukemia (MPAL) painorapwa neB-ALL chemotherapy. Zvimwe zvinangwa zvechidzidzo ichi zvinosanganisira kuongorora kuti kurapa vese varume nevakadzi nehurefu hwakafanana hwemakemotherapy inochengetedza mhedzisiro yevanhurume vakamborapwa kwegore rekuwedzera zvichienzaniswa nevasikana, pamwe nekuongorora nzira dzakanakisa dzekubatsira varwere kutevedzera pamuromo. chemotherapy marongero. Chekupedzisira, chidzidzo ichi chichava chekutanga kuongorora zvinobuda muzvidzidzo zvakaparadzirwa B-cell Lymphoblastic Leukemia (B LLy) kana Mixed Phenotype Acute Leukemia (MPAL) painorapwa neB-ALL chemotherapy.
Nzvimbo: 189 nzvimbo
Inokurumidza kana Yakajairwa BEP Chemotherapy Mukurapa Varwere vane Zvepakati kana Varombo-Njodzi Metastatic Germ Cell Tumors.
Ichi chisinganzwisisike chikamu chechitatu cheyedzo yekuongorora kuti yakadii kukurumidza chirongwa chebluomycin sulphate, etoposide phosphate, uye cisplatin (BEP) chemotherapy inoshanda ichienzaniswa neyakajairwa chirongwa cheBEP chemotherapy pakurapa varwere vane chepakati kana varombo-vane hutachiona hutachiona hutachiona hwakapararira kune vamwe nzvimbo mumuviri (metastatic). Zvinodhaka zvinoshandiswa mukemotherapy, senge bleomycin sulphate, etoposide phosphate, uye cisplatin, zvinoshanda nenzira dzakasiyana kumisa kukura kwemarara maseru, kungave nekuuraya iwo maseru, nekuamisa iwo kubva pakupatsanuka, kana nekuamisa iwo kubva pakupararira. Kupa BEP chemotherapy pane inokurumidza, kana "kukurumidza" chirongwa kunogona kushanda zvirinani nemhedzisiro mhedzisiro pakurapa varwere vane wepakati kana varombo-njodzi metastatic germ cell tumors zvichienzaniswa neyakajairwa purogiramu.
Nzvimbo: 139 nzvimbo
Bvumira mhinduro auto-Refresher